首页> 美国卫生研究院文献>other >Inhibition of NF-kappa B signaling restores responsiveness of castrate resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor variants expression
【2h】

Inhibition of NF-kappa B signaling restores responsiveness of castrate resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor variants expression

机译:NF-κB信号的抑制通过降低雄激素受体变异体表达恢复去势抵抗性前列腺癌细胞对抗雄激素治疗的反应性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Androgen receptor splicing variants (ARVs) which lack the ligand-binding domain (LBD) are associated with the development of castration-resistant prostate cancer (CRPC), including resistance to the new generation of high affinity anti-androgens. However, the mechanism by which ARVs expression is regulated is not fully understood. In this study, we show that activation of classical NF-κB signaling increases the expression of ARVs in prostate cancer (PCa) cells and converts androgen sensitive PCa cells to become androgen insensitive; while, downregulation of NF-κB signaling inhibits ARVs expression and restores responsiveness of CRPC to anti-androgen therapy. In addition, we demonstrated that combination of anti-androgen with NF-κB targeted therapy inhibits efficiently tumor growth of human CRPC xenografts. These results indicate that induction ARVs by activated NF-κB signaling in PCa cells is a critical mechanism by which the PCa progresses to CRPC. This has important implications since it can prolong the survival of CRPC patients by restoring the tumors to once again respond to conventional androgen-deprivation therapy (ADT).
机译:缺乏配体结合域(LBD)的雄激素受体剪接变体(ARV)与去势抵抗性前列腺癌(CRPC)的发展有关,包括对新一代高亲和力抗雄激素的抵抗。但是,ARVs表达调控的机制尚未完全了解。在这项研究中,我们表明经典NF-κB信号的激活增加了前列腺癌(PCa)细胞中ARV的表达,并将雄激素敏感的PCa细胞转化为对雄激素不敏感的细胞;同时,NF-κB信号的下调抑制了ARVs的表达并恢复了CRPC对抗雄激素治疗的反应性。此外,我们证明了抗雄激素与NF-κB靶向疗法的组合可有效抑制人CRPC异种移植物的肿瘤生长。这些结果表明,通过激活的NF-κB信号在PCa细胞中诱导ARVs是PCa进入CRPC的关键机制。这具有重要意义,因为它可以通过使肿瘤恢复对常规雄激素剥夺疗法(ADT)的反应来延长CRPC患者的生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号